![Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study]()
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world studyYang, Guangjian; Ma, Di; Xu, Haiyan; Yang, Lu; Li, Junling; Xing, Puyuan; Hao, Xuezhi; Wang, Yan · Cancer Medicine · 2019